Bank of New York Mellon Corp Has $21.25 Million Stake in Twist Bioscience Corporation (NASDAQ:TWST)

Bank of New York Mellon Corp trimmed its position in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 6.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 541,197 shares of the company's stock after selling 38,379 shares during the period. Bank of New York Mellon Corp owned approximately 0.91% of Twist Bioscience worth $21,247,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of TWST. Farther Finance Advisors LLC lifted its position in shares of Twist Bioscience by 18.5% during the first quarter. Farther Finance Advisors LLC now owns 6,435 shares of the company's stock worth $251,000 after acquiring an additional 1,006 shares in the last quarter. GAMMA Investing LLC grew its position in Twist Bioscience by 6,499.1% in the 1st quarter. GAMMA Investing LLC now owns 29,366 shares of the company's stock worth $1,153,000 after purchasing an additional 28,921 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in Twist Bioscience in the 1st quarter worth $396,000. SG Americas Securities LLC bought a new position in shares of Twist Bioscience during the 1st quarter valued at about $893,000. Finally, Vanguard Group Inc. raised its position in shares of Twist Bioscience by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock valued at $269,860,000 after buying an additional 189,791 shares in the last quarter.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $35.85 on Friday. The business has a fifty day moving average of $33.61 and a 200-day moving average of $39.59. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.24 and a current ratio of 4.51. The firm has a market cap of $2.15 billion, a PE ratio of -11.03 and a beta of 2.41. Twist Bioscience Corporation has a twelve month low of $27.12 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The firm had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative net margin of 54.98% and a negative return on equity of 33.48%. On average, equities research analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In related news, SVP Paula Green sold 1,101 shares of the stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $41,452.65. Following the completion of the sale, the senior vice president directly owned 129,380 shares of the company's stock, valued at approximately $4,871,157. This trade represents a 0.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Emily M. Leproust sold 1,678 shares of the firm's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $35.76, for a total value of $60,005.28. Following the completion of the sale, the chief executive officer directly owned 645,782 shares of the company's stock, valued at $23,093,164.32. This represents a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,961 shares of company stock worth $877,006 over the last quarter. 3.01% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on TWST. Barclays decreased their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Guggenheim reaffirmed a "buy" rating and set a $50.00 target price on shares of Twist Bioscience in a research note on Tuesday, May 6th. The Goldman Sachs Group lowered their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. JPMorgan Chase & Co. cut their price objective on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Finally, Robert W. Baird dropped their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $50.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.